ArticleClinics (Sao Paulo, Brazil)2026
Predictors of survival and renal replacement therapy in anca-associated vasculitis with renal involvement: An 11-year real-world cohort from North Macedonia.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntineutrophil Cytoplasmic Antibody (ANCA) - Associated Vasculitis (AAV) is a rare systemic small-vessel vasculitis in which renal involvement is a major determinant of morbidity and survival. Despite therapeutic advances, many patients still present with advanced kidney disease. Data from Southeast Europe remain limited.
methodsWe conducted an 11-year retrospective observational study of adult patients with AAV and renal involvement treated at national nephrology center in North Macedonia. Demographic, clinical, laboratory, treatment, and outcome data were analyzed. Predictors of mortality were evaluated using Cox proportional hazards models, while renal outcomes were assessed using Fine-Gray competing risk regression with death treated as a competing event.
resultsForty-two patients were included (57.1% male; mean age 56.5 ± 14.9 years). Renal involvement was severe at presentation, with a mean eGFR of 26.2 ± 16.4 mL/min/1.73 m
conclusionThis first national cohort from North Macedonia confirms that AAV with renal involvement presents with advanced kidney dysfunction, a compressed time to RRT, and substantial early mortality. Baseline renal function remains the dominant determinant of renal outcome, underscoring the need for earlier diagnosis and structured referral pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.